INTRODUCTION Optimizing the use of antibacterial medicines is an accepted strategy to combat the antibacterial resistance. Availability of reliable antibacterial consumption (ABC) data is a prerequisite to implement this strategy. OBJECTIVES To quantify and describe the national ABC in Sri Lanka and to examine any differences in the consumption between public and private sector. METHODS The methodology for this survey was adapted from World Health Organization (WHO) methodology for a global programme on surveillance of antimicrobial consumption. Aggregate data on national consumption of systemic antibacterials (J01- Anatomical Therapeutic Chemical Classification (ATC) for 2017 were retrospectively extracted from all available data sources and classified using ATC classification. Quantity of consumption was converted to Defined Daily Doses (DDDs). Data are presented as total consumption and comparison between the public and private sector. Selected key quality indicators of ABC were compared between these two sectors. FINDINGS From the available data sources, the total ABC in 2017 was 343.46 million DDDs. Private sector consumption accounted for 246.76 million DDDs compared to 97.96 million DDDs distributed to entire public sector by the Ministry of Health. Beta-lactam-penicillins antibacterial group accounted for 58.79% in public sector compared to 27.48% in private sector while macrolides, quinolones and other beta-lactam antibacterials accounted for 60.51% in the private compared to 28.41% in public sector. Consumption of Reserve group antibacterials was negligible, and limited to private sector. Watch category antibacterials accounted for 46%, 24% and 54% of the total, public and private sector consumption, respectively. CONCLUSIONS A disproportionately higher use of broad spectrum and Watch category antibacterials was observed in the private sector which needs further study. This national consumption survey highlights the need and provides the opening for establishment of ABC surveillance in Sri Lanka.

中文翻译：

---

斯里兰卡抗菌药物消费全国调查。


引言优化抗菌药物的使用是对抗抗菌药物耐药性的公认策略。获得可靠的抗菌药物消耗（ABC）数据是实施这一策略的先决条件。目标 量化和描述斯里兰卡的国家 ABC，并检查公共和私营部门之间消费的差异。方法 本次调查的方法改编自世界卫生组织 (WHO) 抗菌药物消费监测全球计划的方法。从所有可用数据源中回顾性提取了 2017 年全国全身性抗菌药物消费量的汇总数据（J01-解剖治疗化学分类（ATC）），并使用 ATC 分类进行分类。消费量转换为每日规定剂量（DDD）。数据呈现公共部门和私营部门的消费总量以及对这两个部门的 ABC 关键质量指标进行了比较。 结果 从现有数据来看，2017 年的 ABC 总量为 343.46 百万 DDD，占 246.76 百万 DDD。相比之下，卫生部向整个公共部门分发了 9796 万个 DDD，公共部门占 58.79%，私营部门占 27.48%，而大环内酯类、喹诺酮类和其他 β-内酰胺类抗菌药物占 60.51%。与公共部门的 28.41% 相比，私营部门的储备组抗菌药物的消费量可以忽略不计，并且仅限于私营部门。手表类抗菌药物分别占公共和私营部门消费总量的 46%、24% 和 54%。 结论 私营部门对广谱和观察类抗菌药物的使用比例过高，这需要进一步研究。这项全国消费调查强调了斯里兰卡建立 ABC 监测的必要性并提供了机会。